FUJIFILM Medical Systems

Announcement

August 17th, 2020
FUJIFILM Medical Systems U.S.A., Inc. Strengthens Healthcare Portfolio with Addition of In Vitro Diagnostics Solutions. FUJIFILM Wako Diagnostics U.S.A. Corporation will become part of FUJIFILM Medical Systems U.S.A., Inc.


Lexington, Mass., August 17, 2020 – FUJIFILM Medical Systems U.S.A., Inc. announced today that effective October 1, 2020, it will add In Vitro Diagnostics (IVD) to its portfolio of healthcare solutions with the integration of FUJIFILM Wako Diagnostics U.S.A. Corporation, a provider of IVD and life science products. The integration will enhance FUJIFILM Medical Systems U.S.A. Inc.’s portfolio of diagnostic solutions for its healthcare customers through the addition of IVD clinical lab reagents and biomarkers. “With an established portfolio of diagnostic imaging solutions to enable treatment planning, diagnosis and healthcare IT, we look forward to expanding our solutions to include IVD,” said Jun Higuchi, president and chief executive officer, FUJIFILM Medical Systems U.S.A., Inc. “The addition of IVD to our diagnostic portfolio will enable us to provide clinicians with tools to assess risks of disease development through our biomarkers and our existing diagnostic imaging solutions.” FUJIFILM Wako Diagnostics has an established portfolio of biomarkers to assess the risk for the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease. Its IVD portfolio of solutions also includes IVD reagents and systems focused on areas including disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes. The new IVD group will be led by Hidetoshi (Henry) Izawa, vice president of modality solutions and clinical affairs, FUJIFILM Medical Systems U.S.A., Inc. As part of his current role, Mr. Izawa oversees digital radiography, computed radiography and women’s health groups. Previously, he was responsible for radiology, IVD and endoscopy for FUJIFILM France, and was the Head of Modality for Europe. “This integration will enable us to leverage our expanded resources at FUJIFILM Medical Systems U.S.A., Inc. to offer enhanced clinical support and customer service to IVD customers,” said Henry Izawa, vice president of modality solutions and clinical affairs, FUJIFILM Medical Systems U.S.A., Inc. “We are thrilled to welcome the talented men and women of FUJIFILM Wako Diagnostics U.S.A. Corporation to our group to accelerate new innovations in IVD.” To learn more about Fujifilm’s comprehensive healthcare solutions, visit www.fujifilmhealthcare.com.

For our complete announcement, please click here.

HCC Risk Biomarkers
 

Adding the two biomarkers, AFP-L3 and DCP, to your current HCC surveillance practice can increase your chances of detecting early HCC. These tests are available now through major reference laboratories in Japan, the United States and Canada.

More

Clinical Diagnostic Reagents

Wako is a comprehensive manufacturer of Clinical Diagnostic reagents that are of the highest quality and good value to performance. Our products are the result of dedication to the field of in vitro diagnostics.

More

Research Reagents
 

Wako is a leading manufacturer of the highest quality chemistry reagents worldwide. Our products are the result of dedication to the field of laboratory science and research development. Our superior research reagents are easy to use and have a robust history of utilization in academia.

More

Ordering



Use the order form (pdf)
for your convenience,
or click icon above to open.

Call us toll free:
877-714-1924

Fax to:
804-271-0449